ABSTRACT
PURPOSE: Healthy ageing is associated with higher levels of glutathione. The study aimed to determine whether long-term dietary fortification with cysteine increases cysteine and glutathione pools, thus alleviating age-associated low-grade inflammation and resulting in global physiological benefits. METHODS: The effect of a 14-week dietary fortification with cysteine was studied in non-inflamed (NI, healthy at baseline) and in spontaneously age-related low-grade inflamed (LGI, prefrail at baseline) 21-month-old rats. Fifty-seven NI rats and 14 LGI rats received cysteine-supplemented diet (4.0 g/kg of free cysteine added to the standard diet containing 2.8 g/kg cysteine). Fifty-six NI rats and 16 LGI rats received a control alanine-supplemented diet. RESULTS: Cysteine fortification in NI rats increased free cysteine (P < 0.0001) and glutathione (P < 0.03) in the liver and the small intestine. In LGI rats, cysteine fortification increased total non-protein cysteine (P < 0.0007) and free cysteine (P < 0.03) in plasma, and free cysteine (P < 0.02) and glutathione (P < 0.01) in liver. Food intake decreased over time in alanine-fed rats (r² = 0.73, P = 0.0002), whereas it was constant in cysteine-fed rats (r² = 0.02, P = 0.68). Cysteine fortification did not affect inflammatory markers, mortality, body weight loss, or tissue masses. CONCLUSION: Doubling the dietary intake of cysteine in old rats increased cysteine and glutathione pools in selected tissues. Additionally, it alleviated the age-related decline in food intake. Further validation of these effects in the elderly population suffering from age-related anorexia would suggest a useful therapeutic approach to the problem.
Subject(s)
Aging , Anorexia/prevention & control , Antioxidants/therapeutic use , Appetite Regulation , Cysteine/therapeutic use , Dietary Supplements , Glutathione/metabolism , Animals , Anorexia/blood , Anorexia/immunology , Anorexia/metabolism , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/adverse effects , Antioxidants/metabolism , Cysteine/adverse effects , Cysteine/blood , Cysteine/metabolism , Dietary Supplements/adverse effects , Energy Intake , Enteritis/blood , Enteritis/immunology , Enteritis/metabolism , Enteritis/prevention & control , Hepatitis/blood , Hepatitis/immunology , Hepatitis/metabolism , Hepatitis/prevention & control , Homeostasis , Inflammation Mediators/blood , Inflammation Mediators/metabolism , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestine, Small/immunology , Intestine, Small/metabolism , Liver/immunology , Liver/metabolism , Male , Oxidative Stress , Rats, WistarABSTRACT
BACKGROUND: Eosinophilic gastrointestinal disorders (EGIDs) are disorders characterized by primary eosinophil inflammation in the gastrointestinal tract. There are a small number of reports of eosinophil infiltration in gastrointestinal tracts presenting as EGIDs in infants. In this study, we present Japanese cases of EGIDs in infants. METHODS: Five patients diagnosed with or strongly suspected to have EGIDs in our hospital from 2008 to 2010 were reviewed. Radiographic contrast enema examinations and/or endoscopies were performed in 4 and 3 patients, respectively. RESULTS: There were patients with eosinophilic colitis (1 suspected and 2 biopsy-proven), a patient who was suspected of having allergic eosinophilic enterocolitis, and a patient with eosinophilic gastroenteritis associated with pediatric hypereosinophilic syndrome. CONCLUSIONS: The causes and clinical findings of patients with intestinal eosinophil inflammation vary. Therefore, deliberate examination and observation are important for patients with infantile EGID.
Subject(s)
Enteritis , Eosinophilia , Gastritis , Colon/pathology , Congenital Abnormalities/pathology , Constriction, Pathologic/pathology , Eczema/complications , Enteritis/blood , Enteritis/complications , Enteritis/diagnosis , Enteritis/etiology , Enteritis/pathology , Enteritis/therapy , Eosinophilia/blood , Eosinophilia/complications , Eosinophilia/diagnosis , Eosinophilia/etiology , Eosinophilia/pathology , Eosinophilia/therapy , Eosinophils/pathology , Feces/cytology , Female , Gastric Mucosa/pathology , Gastritis/blood , Gastritis/complications , Gastritis/diagnosis , Gastritis/etiology , Gastritis/pathology , Gastritis/therapy , Humans , Hypereosinophilic Syndrome/blood , Hypereosinophilic Syndrome/complications , Hypereosinophilic Syndrome/pathology , Immunoglobulin E/blood , Immunoglobulin E/immunology , Infant , Infant, Newborn , Intestinal Mucosa/pathology , Japan , Male , Milk Hypersensitivity/complications , Milk Hypersensitivity/immunology , Myocarditis/complications , Occult Blood , Prednisolone/therapeutic use , Rectum/pathology , SyndromeABSTRACT
Multiple mucosal immune factors, such as TNF-alpha and IL-1beta, are thought to be key mediators involved in inflammatory bowel disease. We evaluated the role of the pro-inflammatory cytokine TNF-alpha on nitric oxide synthase (NOS) expression in indomethacin-induced jejunoileitis in rats. Jejunoileitis was induced in rats with subcutaneous injections of indomethacin (7.5 mg/kg) 24 h apart for two consecutive days, and animals were randomized into four groups. Group 1 received only indomethacin. Group 2 was treated with a daily dose of phosphodiesterase (PDE) inhibitor (theophylline or pentoxifylline) by oral gavage for 2 days before and 4 days after indomethacin. Group 3 received a single dose of anti-TNF-alpha monoclonal antibody (TNF-Ab, IP) 30 min before indomethacin. Group 4 was treated with 1 h hyperbaric oxygenation (HBO(2)) for 5 days after indomethacin. Rats were sacrificed at 12 h or 4 days after final indomethacin injection. PDE inhibitor, TNF-Ab, or HBO(2) treatment significantly decreased indomethacin-induced ulceration, myeloperoxidase activity, and disease activity index. Although indomethacin significantly increased serum TNF-alpha and nitrate/nitrite (NOx) concentrations above control values at 12 h, inducible NOS (iNOS) expression was detected only at day 4. Serum IL-1beta levels did not change at 12 h but increased 4-fold after 4 days. Indomethacin had no effect on constitutive NOS. Treatment with PDE inhibitor, TNF-Ab, or HBO(2) significantly reduced serum/tissue TNF-alpha, IL-1beta, NOx, and iNOS expression. Our data show TNF-alpha plays an early pro-inflammatory role in indomethacin-induced jejunoileitis. Additionally, down-regulation of NOx by PDE inhibitors, TNF-Ab, or HBO(2) suggests that TNF-alpha modulates iNOS expression.
Subject(s)
Enteritis/metabolism , Ileitis/metabolism , Indomethacin/toxicity , Jejunal Diseases/metabolism , Nitric Oxide Synthase Type II/metabolism , Tumor Necrosis Factor-alpha/physiology , Animals , Dose-Response Relationship, Drug , Enteritis/blood , Enteritis/chemically induced , Hyperbaric Oxygenation , Ileitis/blood , Ileitis/chemically induced , Ileum/enzymology , Ileum/metabolism , Interleukin-1beta/blood , Interleukin-1beta/metabolism , Intestinal Mucosa/enzymology , Intestinal Mucosa/metabolism , Jejunal Diseases/blood , Jejunal Diseases/chemically induced , Jejunum/enzymology , Jejunum/metabolism , Male , Nitrates/blood , Nitrites/blood , Peroxidase/metabolism , Phosphodiesterase Inhibitors/pharmacology , Random Allocation , Rats , Rats, Sprague-Dawley , Severity of Illness Index , Specific Pathogen-Free Organisms , Time Factors , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/bloodABSTRACT
We previously showed that phosphorylation of p70 S6 kinase (p70(S6k)) in the intestine is increased during viral enteritis. In this study, we hypothesized that during rotavirus infection, oral Arg, which stimulates p70(S6k) activation, will further stimulate intestinal protein synthesis and mucosal recovery, whereas the p70(S6k) inhibitor rapamycin (Rapa) will inhibit mucosal recovery. Newborn piglets were fed a standard milk replacer diet supplemented with Arg (0.4 g x kg(-1) x d(-1), twice daily by gavage), Rapa (2 mg x m(-2) x d(-1)), Arg + Rapa, or saline (controls). They were infected on d 6 of life with porcine rotavirus. Three days postinoculation, we measured the piglets' body weight, fecal rotavirus excretion, villus-crypt morphology, epithelial electrical resistance in Ussing chambers, and p70(S6k) activation by Western blotting and immunohistochemistry. We previously showed a 2-fold increase in jejunal protein synthesis during rotavirus diarrhea. In this experiment, Arg stimulated jejunal protein synthesis 1.3-fold above standard medium, and the Arg stimulation was partially inhibited by Rapa. Small bowel stimulation of p70(S6k) phosphorylation and p70(S6k) levels were inhibited >80% by Rapa. Immunohistochemistry revealed a major increase of p70(S6k) and ribosomal protein S6 phosphorylation in the crypt and lower villus of the infected piglets. However, in Arg-treated piglets, p70(S6k) activation occurred over the entire villus. Jejunal villi of the Rapa-treated group showed inactivation of p70(S6k) and a decrease in mucosal resistance (reflecting increased permeability), the latter of which was reversed by Arg. We conclude that, early in rotavirus enteritis, Arg has no impact on diarrhea but augments intestinal protein synthesis in part by p70(S6k) stimulation, while improving intestinal permeability via a mammalian target of rapamycin/p70(S6k)-independent mechanism.
Subject(s)
Arginine/pharmacology , Enteritis/metabolism , Intestinal Mucosa/enzymology , Protein Biosynthesis/drug effects , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , Rotavirus Infections/metabolism , Swine/virology , Animals , Dietary Supplements , Enteritis/blood , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Immunohistochemistry , Intestinal Mucosa/virology , Jejunum/pathology , Rotavirus Infections/enzymology , Sirolimus/pharmacology , Swine/metabolismABSTRACT
Phosphorus-calcium metabolism was studied in 74 patients with malabsorption syndrome that had developed as a result of chronic enteritis or after resection of the small intestine. The results of the treatment of 21 patients who received diets with Ca/P ratio--1:1.5 (bread enriched with Ca was included into the ration) have shown that dietotherapy led to the correction of the initial hypocalcemia and hyperphosphatemia.
Subject(s)
Calcium, Dietary/administration & dosage , Calcium/blood , Malabsorption Syndromes/blood , Phosphorus/blood , Chronic Disease , Enteritis/blood , Enteritis/complications , Enteritis/diet therapy , Humans , Malabsorption Syndromes/diet therapy , Malabsorption Syndromes/etiology , Phosphorus/administration & dosage , Postoperative Complications/blood , Postoperative Complications/diet therapyABSTRACT
The clinical effectiveness of alvesin, a mixture of pure amino acids, balanced by the amino acid composition, was studied in the treatment of patients with chronic diseases of the small intestine. The drug was well tolerated by the patients after its parenteral administration. A high clinical effect of alvesin was recorded in 98 patients suffering from chronic enteritis, celiac disease, general variable immunodeficiency. The optimal dose of the drug was determined.